People with advanced pancreatic cancer taking an experimental daily pill lived nearly twice as long as those receiving ...

(Corrects paragraph 5 to say "doubled" not "reduced") By Julie Steenhuysen CHICAGO, May 31 (Reuters) - Revolution Medicine's ...

A new report estimates speeding up FDA drug approvals by one year could generate over $10 trillion in economic value from ...

The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who ...

The agency will now treat Replimune’s RP1 as ‘an urgent matter.’ ...

The highly anticipated results of a clinical trial for the pill, daraxonrasib, have been released, giving doctors hope for ...

(Corrects to clarify the total number of patients in the study in paragraph 10) May 27 (Reuters) - The U.S. Food and Drug ...

CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill ...

CVS Caremark will start covering Eli Lilly's Foundayo and resume covering its Zepbound obesity drugs in the next several ...

A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the dangerous liver ...

Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the ...

FDA warns against using over-the-counter skin lightening products due to high levels of mercury or hydroquinone, which can ...